|
Volumn 39, Issue 12, 2000, Pages 881-886
|
Cancer of the male breast
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CARCINOEMBRYONIC ANTIGEN;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
ESTROGEN;
ESTROGEN RECEPTOR;
FLUOROURACIL;
METHOTREXATE;
PROGESTERONE RECEPTOR;
PROTEIN;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
TAMOXIFEN;
ADJUVANT CHEMOTHERAPY;
BODY WEIGHT DISORDER;
BREAST CANCER;
BREAST DISEASE;
CANCER INCIDENCE;
CANCER RADIOTHERAPY;
CANCER STAGING;
CLINICAL FEATURE;
CLINICAL TRIAL;
DIAGNOSTIC VALUE;
DIFFERENTIAL DIAGNOSIS;
DRUG ACTIVITY;
ESTROGEN THERAPY;
GENETIC SUSCEPTIBILITY;
HEMATOLOGIC DISEASE;
HISTOPATHOLOGY;
HOT FLUSH;
HUMAN;
MALE BREAST;
MASTECTOMY;
MENTAL DISEASE;
METASTASIS;
PHYSICAL EXAMINATION;
PREVALENCE;
PROGNOSIS;
PROSTATE CANCER;
REVIEW;
RISK FACTOR;
UNITED STATES;
BREAST NEOPLASMS, MALE;
HUMANS;
INCIDENCE;
MALE;
NEOPLASM STAGING;
PROGNOSIS;
UNITED STATES;
|
EID: 0034496148
PISSN: 00119059
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1365-4362.2000.00007.x Document Type: Review |
Times cited : (16)
|
References (50)
|